Serum, Bharat Biotech vaccines get restricted use approval from DCGI

While the Oxford-AstraZeneca vaccine made by Serum Institute here has 70.42% efficacy, Bharat Biotech's still does not have efficacy data as trials are underway in India

Coronavirus, vaccine, covid, drugs, clinical trials

Covaxin is based on highly purified and inactivated two-dose Sars-Cov-2 vaccine manufactured in a vero cell manufacturing platform

Ruchika ChitravanshiSohini Das
India’s drug regulator on Sunday gave its final approval to the Oxford-AstraZeneca and Bharat Biotech coronavirus vaccines for restricted use in an emergency situation, giving the country its first two shots for immunising its vast population in the coming weeks.

While the Oxford-AstraZeneca vaccine, manufactured by Serum Institute of India (SII), has 70.42 per cent efficacy, the indigenous vaccine from Bharat Biotech does not have efficacy details because the trials are underway. It is doing a study of 25,800 volunteers and around 22,500 participants have been given at least one jab.

Both vaccines can be stored at 2-8 degrees Celsius and the companies have been stockpiling them for dispatch once the approvals come.

First Published: Jan 03 2021 | 8:08 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to